Demis Hassabis, co-founder of Google DeepMind, highlighted AI's revolutionary potential in healthcare at the FT Pharma and Biotech Summit. He emphasized that AI could surpass the internet's impact, likening it to electricity or fire. His work with AlphaFold, which earned him a Nobel Prize, showcases AI's ability to solve complex biological problems.
Hassabis founded Isomorphic Labs to leverage AI for drug discovery, focusing on algorithmic innovation. Collaborations with major pharmaceutical companies like Eli Lilly and Novartis underscore the growing importance of AI in finding cures for diseases. Despite the optimism, he stressed the need for careful regulation and research to mitigate potential risks associated with advanced AI systems.
• AI's potential in healthcare is likened to electricity's transformative impact.
• Isomorphic Labs collaborates with major pharma companies for drug discovery.
AlphaFold is an AI program that predicts protein structures, solving a long-standing biological challenge.
Synthetic data generation involves creating artificial data to enhance AI training and model performance.
Google DeepMind is a leader in AI research, known for developing AlphaFold and advancing healthcare applications.
Isomorphic Labs focuses on using AI for drug discovery, emphasizing algorithmic innovation over traditional lab methods.
Pharmaceutical Technology on MSN.com 9month
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.